A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) (NCT06295796), a non-randomized phase 1 study. The primary outcome is Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma.

2. Clinical Question

The scientific focus is pharmacokinetics: how drug concentrations change over time and how much exposure is observed. The primary endpoint is the area under the plasma concentration-time curve from dosing to the last quantifiable sample. The study collects blood samples at specified times after dosing to estimate that exposure. The registry also lists outcomes involving MK-8527-triphosphate in peripheral blood mononuclear cells, as well as adverse events and discontinuations due to adverse events.

This question is descriptive and comparative in purpose, rather than a test of clinical benefit. The registry record does not report estimates of exposure by group, uncertainty around those estimates, or a stated hypothesis to be tested. It therefore does not establish from the posted information whether or how much exposure differs across the renal impairment groups and healthy participants.

3. Trial Design

This is a completed Phase 1, open-label, non-randomized, parallel-group study of MK-8527 in participants with moderate or severe renal impairment and healthy participants. Each group receives a single dose on Day 1. The record lists an enrollment of 18. The study started on 2024-06-20, had a primary completion date of 2025-01-31, and is marked completed.

Because allocation is non-randomized, group membership is not assigned by chance. The groups can be compared descriptively, but they should not be treated as equivalent to randomized treatment arms. Differences between groups could reflect factors associated with group membership as well as renal impairment. The registry explicitly cautions that the arms are not a like-for-like control comparison. The healthy participants provide a reference for the pharmacokinetic assessment, but the design does not make that reference group a randomized control.

Open-label means the registry does not describe masking. This can matter for outcomes that depend on reporting or judgment, such as adverse events, although the pharmacokinetic endpoint is based on measured plasma concentrations. The record identifies the study as parallel, indicating that participants belong to a group rather than crossing between study groups in the described design.

The primary outcome is AUC0-last of MK-8527 in plasma, measured in nM·hr. Blood sampling is specified from predose through 168 hours post dose, including measurements at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours. Secondary outcomes include adverse events, discontinuations due to adverse events, and several measures of MK-8527-triphosphate in peripheral blood mononuclear cells. The registry summary says the study has no hypothesis testing. Details of the statistical analysis plan beyond the listed endpoint descriptions are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: All participants who complied with the protocol sufficiently to ensure that generated data likely exhibited the effects of treatment, according to the underlying scientific model

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma, measured over Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose.

The primary endpoint is the area under the plasma concentration-time curve from time zero to the last quantifiable sample, abbreviated AUC0-last. It is reported in nM·hr, with a geometric mean as the summary measure and a geometric coefficient of variation as the measure of dispersion. The registry defines the endpoint as the area under the concentration-time curve from time zero to the last concentration above the lower limit of quantitation. It states that AUC0-last was calculated using noncompartmental analysis.

As a general statistical concept, an area under a concentration-time curve combines information across measurements taken over time into a summary of exposure during the measured interval. It is useful in pharmacokinetic studies because a single concentration at one time point may not represent the overall concentration profile. The endpoint is limited to the time from dosing to the last quantifiable measurement; it is not the same as exposure extrapolated to an infinite time horizon.

A geometric mean is a way to summarize positive measurements when values are naturally interpreted on a multiplicative scale or are unevenly distributed. The geometric coefficient of variation describes relative spread on that scale. These summaries can help characterize and compare exposure distributions, but they do not by themselves indicate whether group differences are statistically reliable or clinically important. The registry record does not report the group-specific AUC0-last estimates or their uncertainty, so the magnitude and precision of any differences cannot be assessed from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes an open-label, non-randomized, parallel study with a single dose of MK-8527. Its primary pharmacokinetic endpoint is AUC0-last, summarized using a geometric mean and geometric coefficient of variation. The registry identifies noncompartmental analysis as the method used to calculate the endpoint. It also states that there will be no hypothesis testing. Other details of the statistical analysis are not reported in the registry record.

What does AUC0-last represent?

As a general statistical concept, a concentration-time curve traces measured drug concentrations across time after dosing. The area under that curve represents cumulative exposure over the interval being summarized. AUC0-last is bounded by the last quantifiable sample, so it describes exposure only through that measurement rather than requiring an estimate of exposure indefinitely beyond it. The registry specifies samples from predose through 168 hours post dose. Its endpoint definition counts concentrations above the lower limit of quantitation as quantifiable.

Noncompartmental analysis is a general approach to pharmacokinetic calculations that uses the observed concentration-time data without requiring the analyst to specify a particular compartment model for the drug. The registry reports that this approach was used for AUC0-last. It does not provide further computational details, handling rules for missing samples, or the analysis software.

Why use a geometric mean?

As a general explanation, positive pharmacokinetic measurements may vary multiplicatively: a change by a proportion can be more meaningful than a change by a fixed additive amount. A geometric mean summarizes values on this multiplicative scale. The geometric coefficient of variation describes relative spread, rather than expressing dispersion as an additive distance from the mean. These summaries can be useful for describing concentration-derived measures, but they do not replace reporting the underlying observations or uncertainty around a group comparison.

The registry's choice of these summaries does not reveal the distribution of the observed values. Nor does the choice alone establish how comparisons between groups were made. Group-specific geometric means, coefficients of variation, confidence intervals, and any model-based estimates are not reported in the registry record.

What can a confidence interval tell a reader?

As a general statistical concept, a confidence interval gives a range of values compatible with the data and the procedure used to estimate the parameter. Its width conveys precision: a wider interval generally indicates less precise estimation than a narrower one. A confidence interval does not show the probability that a fixed parameter lies in a particular calculated interval. No confidence interval for the primary endpoint is reported in the registry record, so the precision of the exposure estimates cannot be assessed.

How should the group structure be read?

The study uses non-randomized groups for moderate renal impairment, severe renal impairment, and healthy participants. In general, randomization helps balance measured and unmeasured characteristics across comparison groups, while a non-randomized design does not provide that protection. Here, the registry specifically cautions that the arms are not a like-for-like control comparison. The group results, if reported, would need to be interpreted as descriptive comparisons in light of that design.

Open-label status means masking is not described. This is distinct from the measurement of plasma concentrations, which is a laboratory-based endpoint, but open-label conduct can be relevant to how some outcomes are reported or assessed. The registry does not describe blinding of laboratory staff or any other safeguards, so those details should not be assumed.

What does the no-hypothesis-testing statement imply?

The registry says that the study will have no hypothesis testing. In general, hypothesis testing evaluates data against a stated null hypothesis using a prespecified decision procedure. A study without hypothesis testing may still collect and summarize outcomes, but a formal significance test is not the stated basis for its purpose. The record does not give a statistical analysis plan, prespecified contrast, significance threshold, or inferential model. Those details are not reported in the registry record.

For a descriptive pharmacokinetic study, estimates and their uncertainty can be more informative than a binary statistical decision. Yet those descriptive estimates are also absent from the posted record. The reader should therefore distinguish the rationale and measurement plan from the results needed to judge exposure patterns.

The registry's sample-size assumptions, where used for planning illustrations, describe hypothetical planning rather than observed study results or observed power. The record does not report a sample-size justification for the trial itself. A planned sample size cannot substitute for observed outcome estimates, and it cannot show how precise the actual pharmacokinetic comparisons were.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary pharmacokinetic endpoint and multiple secondary outcomes, including adverse events, discontinuations due to adverse events, and measures of MK-8527-triphosphate in peripheral blood mononuclear cells. It states that there will be no hypothesis testing. It does not report a multiplicity adjustment strategy, an ordered testing procedure, or a statistical analysis plan addressing multiple outcomes. Those details are not reported in the registry record.

As a general statistical concept, when many outcomes or comparisons are tested, the chance of obtaining at least one apparently notable result by chance can increase. Methods for controlling multiplicity may be used when formal inferential claims are intended. In a study described as having no hypothesis testing, it is particularly important not to interpret outcome listings as evidence that significance tests were performed or that any particular multiplicity method was used.

The registry defines the primary analysis population as participants who complied with the protocol sufficiently to ensure that generated data likely exhibited treatment effects according to the underlying scientific model. It does not report how many participants met that definition, how exclusions were handled, or whether other analysis populations were used. Details about missing concentration measurements, withdrawals, imputation, or sensitivity analyses are not reported in the registry record.

These omissions limit assessment of how incomplete data could affect the pharmacokinetic estimates and how consistently participants were included across outcomes. They also prevent a reader from determining whether analyses were prespecified or how deviations from the intended assessment were addressed. No assumptions about missingness or analysis populations should be inferred from the endpoint description alone.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The registry safety summary lists six participants at risk in each of the moderate renal impairment, severe renal impairment, and healthy groups. For each group, the serious adverse event field records zero affected, and the other adverse event field also records zero affected. Deaths are recorded as zero in each group. These are the counts entered in the posted safety summary.

These figures should be read as registry entries for the stated event categories, not as proof that no adverse experiences of any kind occurred or that the medicine is safe in every setting. The secondary outcomes include the number of participants who experience one or more adverse events and the number who discontinue due to an adverse event. Detailed results for those outcomes are not reported in the registry record. The posted summary also does not describe event timing, severity, relatedness, or individual event terms; no serious adverse event terms are listed.

As a general statistical point, a zero count in a small group does not establish that the underlying risk is zero. Safety interpretation depends on the completeness of event collection, the duration of follow-up, the kinds of events tracked, and the precision of the estimate. Those details are not fully reported in the registry record. The figures are therefore a limited description of the posted safety fields, not a comprehensive safety conclusion.

12. What the Result Does, and Does Not, Mean

The record establishes that MK-8527 was studied as a single dose in participants with moderate or severe renal impairment and healthy participants, with pharmacokinetics, safety, and tolerability as the objectives. It specifies AUC0-last of MK-8527 in plasma as the primary endpoint and describes scheduled blood sampling and noncompartmental calculation. It also reports limited safety counts. These are meaningful features of the study record, but they are not the primary pharmacokinetic results.

The record does not report group-specific AUC0-last estimates, their dispersion, confidence intervals, or other numerical comparisons. Consequently, it does not show the observed magnitude, direction, or precision of any difference in plasma exposure among the groups. It also does not report a hypothesis test, and the summary explicitly states that there will be no hypothesis testing. The absence of reported estimates should not be interpreted as evidence that exposure was equal or different.

The design also limits what a group comparison could establish. Allocation was non-randomized, and the registry cautions that the arms are not a like-for-like control comparison. As a general statistical principle, differences between non-randomized groups can be associated with characteristics beyond the group label. Descriptive comparisons would not by themselves demonstrate that renal impairment caused an observed difference.

The safety summary lists zero affected for both serious and other adverse event fields in each group, and zero deaths in each group. These entries do not establish absence of risk. The detailed results for the listed adverse-event and discontinuation outcomes are not reported in the registry record.

Accordingly, the posted information supports a description of study intent, structure, endpoint definition, and selected safety counts. It does not support a conclusion about the size or clinical significance of pharmacokinetic differences, a causal claim, or a broad safety judgment. The record does not report clinical outcomes that would establish whether MK-8527 benefits participants.

13. Why This Trial Matters Statistically

This study addresses a pharmacokinetic question in groups with different renal impairment status and a healthy reference group. Such questions matter statistically because drug concentration measurements collected over time need to be reduced to interpretable summaries, while the groups themselves are not randomized. The record's primary endpoint, AUC0-last, summarizes exposure across the measured concentration-time profile rather than relying on a single measurement.

The endpoint's geometric summary is also relevant. As a general statistical matter, concentration-derived measures may be more naturally described on a multiplicative scale, and a geometric mean with a geometric coefficient of variation gives information about typical exposure and relative variability. However, a summary measure is informative only when its observed value and precision are available. Those primary results are not reported in the registry record.

The non-randomized design highlights the distinction between describing group differences and attributing them to renal impairment. The registry's explicit warning that the arms are not a like-for-like comparison is important: group membership may coincide with other differences, and randomization is not used to balance them. The study's stated absence of hypothesis testing also signals that the record should not be read as a confirmatory statistical test.

Finally, the safety counts illustrate why zero observed events should be interpreted with context. The record lists zero affected in its serious and other adverse event fields for each group, but detailed adverse-event outcome results and fuller event descriptions are not reported. For readers assessing the evidence, the key statistical contribution of this record is its description of a structured pharmacokinetic assessment; its posted results are not sufficiently detailed to quantify exposure differences or provide a comprehensive safety assessment.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpretation is that the registry record does not report the primary outcome estimates. Without group-specific AUC0-last values or measures of their precision, the central pharmacokinetic question cannot be answered from the posted results. The record also does not report numerical results for the listed secondary pharmacokinetic outcomes involving MK-8527-triphosphate.

The design is non-randomized, and the registry cautions that the groups are not a like-for-like control comparison. This limits causal interpretation of any group contrast. The study is open-label, and masking details are not reported. The record does not provide participant characteristics that would allow readers to assess comparability across groups.

The registry states that there will be no hypothesis testing, but it does not report a detailed statistical analysis plan, inferential model, confidence intervals, or approach to multiplicity. It does not report a trial sample-size justification. The primary analysis population is described by a protocol-compliance criterion, but the number included and the handling of participants who did not meet that criterion are not reported in the registry record.

Information about missing concentration measurements, withdrawals, imputation, sensitivity analyses, and the completeness of outcome follow-up is also not reported in the registry record. For safety, the posted summary contains zero affected in serious and other adverse event fields and zero deaths in each group, but detailed results for adverse events and discontinuations are not reported. These gaps constrain both pharmacokinetic and safety interpretation. The registry's completed status does not fill in the missing outcome estimates.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008) — NCT06295796.
• Registry record last updated 2026-02-17; status last verified 2026-01.
• Results first posted 2026-02-17.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

This is a completed Phase 1, open-label, non-randomized, parallel study of a single dose of MK-8527 in participants with moderate or severe renal impairment and healthy participants. The registry lists enrollment of 18 and states that there will be no hypothesis testing. The primary endpoint is plasma AUC0-last, calculated by noncompartmental analysis and summarized with a geometric mean and geometric coefficient of variation.

The record describes planned sampling through 168 hours post dose and lists secondary pharmacokinetic and safety outcomes. It reports zero affected in the serious and other adverse event fields and zero deaths for each group. Primary pharmacokinetic estimates and detailed secondary outcome results are not reported in the registry record. The non-randomized groups should be treated as descriptive comparisons, not like-for-like randomized controls.